Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Total Liabilities (2023 - 2025)

Telix Pharmaceuticals (TLX) posted Total Liabilities of $748.6 million for Q4 2025, up 20.73% on a QoQ basis from $620.1 million in Q4 2024, and up 20.73% year-over-year from $620.1 million in Q4 2024.

Telix Pharmaceuticals (TLX) has 3 years of Total Liabilities data on file, last reported at $748.6 million in Q4 2025.

  • In Q4 2025, Total Liabilities rose 20.73% year-over-year to $748.6 million; the TTM figure through Dec 2025 stood at $748.6 million (up 20.73% YoY), while the FY2025 annual figure was $748.6 million, up 27.44% from the prior year.
  • Total Liabilities advanced to $748.6 million in Q4 2025, from $620.1 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $748.6 million in Q4 2025 and bottomed at $167.3 million in Q4 2023.
  • A 3-year average of $512.0 million and a median of $620.1 million in 2024 frame the typical range for Total Liabilities.
  • Annual changes were most pronounced in 2024 — Total Liabilities surged 270.57% — and 2025, when it gained 20.73%.
  • Year by year, Total Liabilities stood at $167.3 million in 2023, then jumped by 270.57% to $620.1 million in 2024, then grew by 20.73% to $748.6 million in 2025.
  • The last three Total Liabilities figures came in at $748.6 million (Q4 2025), $620.1 million (Q4 2024), and $167.3 million (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Liabilities (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 16.35 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 1.74 Mn
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 731.60 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 177.22 Mn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 19.51 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 7.12 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - 10.44 Mn
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 9.45 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 4.05 Bn
10 Telix Pharmaceuticals 4.52 Bn 4.38 Bn - 748.61 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 748.61 Mn
Dec 31, 2024 620.09 Mn
Dec 31, 2023 167.34 Mn